Eloralintide (LY3841136) is an investigational amylin receptor agonist being developed by Eli Lilly for weight management. It targets the amylin pathway, offering a complementary mechanism to GLP-1 agonists for appetite suppression and metabolic regulation.
Category: Weight Loss & Metabolic. Evidence rating: C (early/mixed human evidence).
Clinical status: Phase II clinical trials by Eli Lilly. Active development as of 2025.
Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling. Amylin is normally co-secreted with insulin from pancreatic beta cells and acts on brain areas controlling appetite.
Safety considerations: Nausea is the most commonly reported adverse effect (consistent with amylin agonist class); Limited long-term safety data available; Clinical trial safety monitoring ongoing.
Reviewed by the PeptideAtlas Editorial Team.
| US regulatory status | Investigational New Drug (IND). Phase II trials ongoing. Not FDA-approved. |
|---|
Related peptides: CAGRILINTIDE + SEMAGLUTIDE.
Eloralintide works through the amylin receptor pathway rather than GLP-1, offering a complementary mechanism for weight loss. They target different satiety pathways.
It is currently in Phase II trials. If successful, it could reach Phase III and potential approval, but this is likely several years away.
Eloralintide (LY3841136) is an investigational amylin receptor agonist being developed by Eli Lilly for weight management. It targets the amylin pathway, which is distinct from GLP-1 approaches.
ELORALINTIDE has been studied for: Weight loss potential, Appetite regulation via amylin pathway, Novel mechanism of action. Eli Lilly investigational compound. Targets amylin pathway distinct from GLP-1.
Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling.
Coverage on this site: Ascletis to Present Superior Weight Loss Data for ASC36_35 FDC at EASD, The Emerging Role of Amylin: Dr. Garvey on CagriSema and the Future of Obesity Care, Eli Lilly opens unprecedented lead over pharma rivals, report says.